CorMedix Stock Price, News & Analysis (NYSEAMERICAN:CRMD)

$0.58 0.01 (1.77 %)
(As of 12/17/2017 04:00 PM ET)
Previous Close$0.58
Today's Range$0.57 - $0.59
52-Week Range$0.32 - $2.48
Volume1.29 million shs
Average Volume980,524 shs
Market Capitalization$38.87 million
P/E RatioN/A
Dividend YieldN/A


CorMedix logoCorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.

Receive CRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
SectorSpecialty & Advanced Pharmaceuticals


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPS($0.61)
Net IncomeN/A
Net Margins-16,300.49%
Return on Equity-318.95%
Return on Assets-227.65%


Outstanding Shares67,030,000

CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions

What is CorMedix's stock symbol?

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

How were CorMedix's earnings last quarter?

CorMedix Inc. (NYSEAMERICAN:CRMD) announced its earnings results on Wednesday, November, 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.08. The biotechnology company earned $0.04 million during the quarter, compared to the consensus estimate of $0.05 million. CorMedix had a negative return on equity of 318.95% and a negative net margin of 16,300.49%. View CorMedix's Earnings History.

When will CorMedix make its next earnings announcement?

CorMedix is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for CorMedix.

Where is CorMedix's stock going? Where will CorMedix's stock price be in 2017?

3 brokers have issued 12-month target prices for CorMedix's shares. Their predictions range from $3.00 to $4.00. On average, they expect CorMedix's share price to reach $3.67 in the next twelve months. View Analyst Ratings for CorMedix.

Are investors shorting CorMedix?

CorMedix saw a increase in short interest during the month of November. As of November 30th, there was short interest totalling 3,699,854 shares, an increase of 12.0% from the November 15th total of 3,303,567 shares. Based on an average daily volume of 739,690 shares, the short-interest ratio is currently 5.0 days. Currently, 5.8% of the company's stock are short sold.

Who are some of CorMedix's key competitors?

Who are CorMedix's key executives?

CorMedix's management team includes the folowing people:

  • Myron M. Kaplan, Chairman of the Board (Age 70)
  • Randy Milby, Chief Executive Officer, Director (Age 61)
  • Robert W. Cook, Chief Financial Officer (Age 60)
  • Antony E. Pfaffle M.D., Chief Scientific Officer, Director (Age 51)
  • Khoso Baluch, Director
  • Gary A. Gelbfish M.D., Director (Age 54)
  • Mehmood Khan M.D., Director (Age 58)
  • Janet M. Dillione, Independent Director (Age 55)
  • Matthew P. Duffy, Independent Director (Age 52)

How do I buy CorMedix stock?

Shares of CorMedix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CorMedix's stock price today?

One share of CorMedix stock can currently be purchased for approximately $0.58.

How big of a company is CorMedix?

CorMedix has a market capitalization of $38.87 million.

How can I contact CorMedix?

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.

MarketBeat Community Rating for CorMedix (CRMD)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CorMedix (NYSEAMERICAN:CRMD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.67$3.67$3.33$4.50
Price Target Upside: 474.53% upside474.53% upside813.99% upside740.02% upside

CorMedix (NYSEAMERICAN:CRMD) Consensus Price Target History

Price Target History for CorMedix (NYSEAMERICAN:CRMD)

CorMedix (NYSEAMERICAN:CRMD) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
10/16/2017HC WainwrightSet Price TargetBuy$4.00View Rating Details
8/10/2017Rodman & RenshawLower Price TargetBuy -> Buy$5.00 -> $3.00View Rating Details
4/24/2017FBR & CoReiterated RatingBuyView Rating Details
(Data available from 12/17/2015 forward)


CorMedix (NYSEAMERICAN:CRMD) Earnings History and Estimates Chart

Earnings by Quarter for CorMedix (NYSEAMERICAN:CRMD)

CorMedix (NYSEAMERICAN CRMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018($0.13)N/AView Earnings Details
11/9/2016Q3 2016($0.15)($0.23)$0.05 million$0.04 millionViewN/AView Earnings Details
8/5/2016Q216($0.11)($0.13)$119.97 million$16.51 millionViewN/AView Earnings Details
5/10/2016Q1($0.09)($0.12)$0.11 million$0.04 millionViewN/AView Earnings Details
11/12/2015Q3($0.13)($0.14)$0.12 million$0.04 millionViewListenView Earnings Details
8/6/2015Q2 2015($0.13)($0.13)$0.08 million$0.12 millionViewN/AView Earnings Details
3/12/2015Q4 2014($0.12)($0.09)$0.08 million$0.09 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.09)($0.09)$0.08 million$0.05 millionViewN/AView Earnings Details
8/14/2014Q2 2014($0.13)($0.26)$0.02 million$0.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


CorMedix (NYSEAMERICAN:CRMD) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for CorMedix (NYSEAMERICAN:CRMD)

No dividend announcements for this company have been tracked by

Insider Trades

CorMedix (NYSEAMERICAN CRMD) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for CorMedix (NYSEAMERICAN:CRMD)
Institutional Ownership by Quarter for CorMedix (NYSEAMERICAN:CRMD)

CorMedix (NYSEAMERICAN CRMD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/12/2017Jr. John L ArmstrongVPBuy20,833$0.48$9,999.84View SEC Filing  
12/12/2017Khoso BaluchCEOBuy104,166$0.48$49,999.68View SEC Filing  
12/12/2017Robert W CookCFOBuy52,083$0.48$24,999.84View SEC Filing  
12/12/2017Steven W LefkowitzDirectorBuy135,416$0.48$64,999.68View SEC Filing  
8/18/2017Khoso BaluchCEOBuy36,207$0.42$15,206.94View SEC Filing  
8/18/2017Mehmood KhanDirectorBuy400,000$0.39$156,000.00View SEC Filing  
8/17/2017Myron KaplanDirectorBuy80,000$0.40$32,000.00View SEC Filing  
8/14/2017Myron KaplanDirectorBuy50,000$0.35$17,500.00View SEC Filing  
5/30/2017Cora M TellezDirectorBuy7,550$0.42$3,171.00View SEC Filing  
5/17/2017Khoso BaluchCEOBuy75,000$0.48$36,000.00View SEC Filing  
5/16/2017Cora M TellezDirectorBuy50,000$0.48$24,000.00View SEC Filing  
5/15/2017Janet DillioneDirectorBuy21,231$0.48$10,190.88View SEC Filing  
5/15/2017Robert W CookCFOBuy50,000$0.50$25,000.00View SEC Filing  
5/1/2017Cora M TellezDirectorBuy4,800$0.66$3,168.00View SEC Filing  
3/30/2017Cora M TellezDirectorBuy1,950$1.66$3,237.00View SEC Filing  
2/28/2017Cora M TellezDirectorBuy1,540$2.10$3,234.00View SEC Filing  
2/7/2017Antony PfaffleInsiderSell10,000$2.00$20,000.00View SEC Filing  
1/30/2017Cora M TellezDirectorBuy1,780$1.79$3,186.20View SEC Filing  
12/30/2016Cora M TellezDirectorBuy1,990$1.58$3,144.20View SEC Filing  
12/9/2016Khoso BaluchCEOBuy10,000$1.77$17,700.00View SEC Filing  
11/30/2016Cora M TellezDirectorBuy1,800$1.80$3,240.00View SEC Filing  
10/31/2016Cora M TellezDirectorBuy1,475$2.15$3,171.25View SEC Filing  
10/21/2016Antony PfaffleInsiderSell20,000$2.23$44,600.00View SEC Filing  
9/22/2016Janet DillioneDirectorBuy15,000$2.66$39,900.00View SEC Filing  
8/25/2016Taunia MarkvickaDirectorBuy18,600$1.65$30,690.00View SEC Filing  
8/19/2016Cora M TellezDirectorBuy12,500$1.73$21,625.00View SEC Filing  
6/21/2016Antony PfaffleInsiderSell29,657$2.14$63,465.98View SEC Filing  
6/20/2016Antony PfaffleInsiderSell10,000$2.16$21,600.00View SEC Filing  
6/15/2016Antony PfaffleInsiderSell4,900$2.21$10,829.00View SEC Filing  
6/13/2016Antony PfaffleInsiderSell5,443$2.27$12,355.61View SEC Filing  
6/9/2016Antony PfaffleInsiderSell10,000$2.38$23,800.00View SEC Filing  
6/8/2016Janet DillioneDirectorBuy3,738$2.67$9,980.46View SEC Filing  
6/3/2016Matthew DuffyDirectorSell46,106$2.73$125,869.38View SEC Filing  
5/31/2016Steven W LefkowitzDirectorSell50,000$2.88$144,000.00View SEC Filing  
5/25/2016Cora M TellezDirectorBuy8,600$2.90$24,940.00View SEC Filing  
5/24/2016Antony PfaffleInsiderSell12,700$2.73$34,671.00View SEC Filing  
5/24/2016Antony PfaffleInsiderSell12,700$2.73$34,671.00View SEC Filing  
5/23/2016Antony PfaffleInsiderSell15,000$2.89$43,350.00View SEC Filing  
5/23/2016Steven W LefkowitzDirectorSell30,000$2.93$87,900.00View SEC Filing  
5/19/2016Antony PfaffleInsiderSell12,300$2.82$34,686.00View SEC Filing  
5/16/2016Antony PfaffleInsiderSell60,000$2.68$160,800.00View SEC Filing  
6/30/2015Randy MilbyCEOBuy1,610$3.88$6,246.80View SEC Filing  
6/23/2015Taunia MarkvickaDirectorBuy4,000$4.81$19,240.00View SEC Filing  
6/15/2015Randy MilbyCEOBuy1,245$5.02$6,249.90View SEC Filing  
6/4/2015Matthew DuffyDirectorSell30,000$6.48$194,400.00View SEC Filing  
5/29/2015Randy MilbyCEOBuy1,026$6.09$6,248.34View SEC Filing  
2/27/2015Randy MilbyCEOBuy1,211$5.16$6,248.76View SEC Filing  
2/13/2015Randy MilbyCEOBuy1,911$3.27$6,248.97View SEC Filing  
1/30/2015Randy MilbyCEOBuy2,016$3.10$6,249.60View SEC Filing  
12/15/2014Randy MilbyCEOBuy4,734$1.32$6,248.88View SEC Filing  
11/28/2014Randy MilbyCEOBuy4,464$1.40$6,249.60View SEC Filing  
11/14/2014Cora M TellezDirectorBuy11,086$1.52$16,850.72View SEC Filing  
11/14/2014Randy MilbyCEOBuy4,111$1.52$6,248.72View SEC Filing  
10/31/2014Randy MilbyCEOBuy3,434$1.82$6,249.88View SEC Filing  
9/30/2014Randy MilbyCEOBuy3,324$1.88$6,249.12View SEC Filing  
9/15/2014Randy MilbyCEOBuy3,654$1.71$6,248.34View SEC Filing  
8/29/2014Randy MilbyCEOBuy3,125$2.00$6,250.00View SEC Filing  
8/15/2014Randy MilbyCEOBuy3,140$1.99$6,248.60View SEC Filing  
7/31/2014Randy MilbyCEOBuy6,250$2.00$12,500.00View SEC Filing  
6/30/2014Randy MilbyCEOBuy2,732$1.83$4,999.56View SEC Filing  
12/13/2013Steven W LefkowitzInsiderBuy18,000$0.78$14,040.00View SEC Filing  
(Data available from 1/1/2013 forward)


CorMedix (NYSEAMERICAN CRMD) News Headlines


SEC Filings


This page is loading this company's SEC Filings. Please wait...

Social Media


CorMedix (NYSEAMERICAN:CRMD) Income Statement, Balance Sheet and Cash Flow Statement


CorMedix (NYSEAMERICAN CRMD) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.